Heart Failure
We recommend
Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?
The journal Vnitřní lékařství recently published the results of a survey conducted among outpatient cardiologists and internists. The aim was to determine the level of diagnosis and treatment of patients with chronic heart failure (CHF) in real-life practice in the Czech Republic, with a special focus on the presence of symptoms in patients who have not yet been diagnosed. We briefly summarize the key findings from this survey.
ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and…
Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in…
Articles on this topic
ESC 2022: Heart Failure with Preserved Ejection Fraction as an Underdiagnosed Problem: How to Increase Its Detection in Everyday Practice?
During this year's European Society of Cardiology Congress (ESC 2022), alarming information…
ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?
Patients with heart failure (HF) can significantly benefit from the inclusion of…
Protective Effect of SGLT2 Inhibitors on Heart Muscle Function - Findings from a Recent Meta-analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the…
ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?
Although the need for pharmacotherapeutic options for patients with heart failure with reduced…
ESC 2022: How to use gliflozins in heart failure? American guidelines now also consider the EMPEROR-Preserved study
One of the important current cardiology topics is the possibility of using gliflozins in…
ESC 2022: Initiating Gliflozin in HFpEF During Hospitalization Can Benefit the Patient. This is Also Evidenced by Experience from the USA
Based on evidence from clinical studies, gliflozins are currently being introduced into…
Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction
The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure…
Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia − A Case Study
In a case study involving a 78-year-old diabetic patient, where only the administration of…
Influence of ARNI on the Efficacy and Safety of Empagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction
Pharmacological inhibition of neprilysin and the AT1 receptor for angiotensin II (ARNI)…
Summary of New American Recommendations for Heart Failure Management
This year, the American Heart Association (AHA), the American College of Cardiology (ACC), and…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Empagliflozin Secures Reimbursement for Heart Failure Treatment
- Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
- Summary of New American Recommendations for Heart Failure Management
- EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction
- Cardio-renal-metabolic syndrome in context
- The Latest Updates of ESC Recommendations for Heart Failure Treatment
Journal on this topic
Related topic